ArticlePatient preference and adherence2025
Patients' Preferences for Attributes of Oral vs Injectable Androgen Deprivation Therapy in Prostate Cancer: A Discrete Choice Experiment.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shared decision-making in prostate cancer treatment: selecting an androgen deprivation therapy option.Future oncology (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Patient involvement in treatment decisions improves outcomes, but data on patients' perspectives of medical androgen deprivation therapy (ADT) options for prostate cancer are limited. This study quantified the impact of multiple attributes of currently available oral and injectable ADTs on patient treatment choice. Patients and Methods: From February to July 2022, US males aged >40 years with localized or advanced prostate cancer completed a cross-sectional survey, including a discrete choice experiment (DCE), to assess preferences for ADT attributes. In each DCE task, participants were asked to choose between two hypothetical ADT treatment profiles defined by administration mode, testosterone surge after initiation, cardiovascular risk, impact on sexual interest, time to testosterone recovery after discontinuation, and out-of-pocket cost. Hierarchical Bayesian models generated preference weights, which were used to estimate attribute relative importance (RI). RIs were compared by five subgroups (cancer stage, race/ethnicity, cardiovascular comorbidities, age, and ADT experience) with two-sample t-tests. Results: A total of 304 participants in the US were included in analyses (median age: 65.0 years). Holding out-of-pocket cost constant, mode of administration, and impact on sexual interest were most important, followed by risk of cardiovascular events. Across all subgroups, on average respondents preferred a once-daily ADT pill over less frequent intramuscular or subcutaneous injections. This preference was significantly stronger among respondents with advanced prostate cancer, those with cardiovascular comorbidities, and among racial/ethnic minorities. Treatment preferences did not differ between ADT-experienced and ADT-naïve respondents. Conclusion: On average, patients preferred to treat prostate cancer by taking a once-daily ADT pill at home rather than receiving less frequent injections. Shared decision-making between healthcare providers and patients, including discussing the benefits, risks, and administration burden of available ADT options, should be encouraged to ensure that patients receive the prostate cancer treatment that is best suited for their care and needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.